A Phase 1 interventional study of CHF10073 (Part 1 - SAD) and Placebo (Part 1 - SAD) in Pulmonary Fibrosis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Pulmonary Fibrosis with a site in Belgium — 4 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Fibrosis · Belgium.
Among the 21 studies in Pulmonary Fibrosis with a site in Belgium, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 19th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →4 of the 21 studies in Pulmonary Fibrosis with a site in Belgium are open now. Recruiting first, the newest first:
Contineum Therapeutics · Sites in Belgium, Argentina, Australia and 16 more countries
Ages 40+
Erasme University Hospital · Sites in Belgium
Ages 18+
Paragonix Technologies · Sites in Belgium, United States
Bristol-Myers Squibb · Sites in Belgium, United States, Argentina and 24 more countries
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 267 across the 18 interventional studies, 150 across the 3 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
Chiesi Farmaceutici S.p.A. has 1 study filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Pulmonary Fibrosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06189820Erasme University HospitalRole of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases | 2027-03-09 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Pulmonary Fibrosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety and tolerability of single ascending doses of inhaled CHF10073 (Part 1 of the study) and multiple ascending doses of CHF10073 (Part 2 of the study). The study will also evaluate the PK profile of study drug in plasma and urine after single and repeated administrations of CHF10073.
In addition, this study will also investigate the metabolites profile of CHF10073 in plasma, urine and faeces (Part 2 of the study) and the PK profile of CHF10073 in the lungs after bronchoalveolar lavage (BAL) (Part 3 of the study).
In addition, the effect of multiple doses of itraconazole on the pharmacokinetic profile of CHF10073 will be investigated (Part 4 of the study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CHF10073 (Part 1 - SAD) · Drug: CHF10073 (Part 2 - MAD) · Drug: CHF10073 (Part 3) · Drug: CHF10073 (Part 4)
Drug: Placebo (Part 1 - SAD) · Drug: Placebo (Part 2 - MAD)
Drug: itraconazole (Part 4) · Drug: CHF10073 (Part 4)
Single doses of CHF10073 for each cohort
Single doses of placebo matching CHF10073 for each cohort
Multiple doses of CHF10073 for each cohort
Single dose of CHF10073
Multiple doses of placebo matching CHF10073 for each cohort
Multiple dose of itraconazole in treatment period 2
Single dose of CHF10073 in Treatment Period 1 and 2
Adverse events and adverse drug reactions
Time frame: Through study completion, around 8 weeks in Part 1, from 10 to 13 weeks in Part 2, for about 7-8 weeks in Part 3 and for about 15 up to 17 weeks in Part 4
Vital signs (Systolic and diastolic Blood Pressure)
Time frame: From screening up to 42 days post-dose
Absolute Values for 12-lead Electrocardiogram (ECG) Recording of HR (heart rate), HR from 0 to 24 hours, hourly HR
Time frame: From screening up to 28 days post-dose
Absolute Values for 12-lead ECGs Recording of Intervals
Intervals recorded: PR, QRS, QT, QTcF
Time frame: From screening up to 28 days post-dose
Change from Baseline for Post-dose 12-lead ECGs Recording of HR, HR from 0 to 24 hours, hourly HR
Time frame: From screening up to 28 days post-dose
Change from Baseline for Post-dose 12-lead ECGs Recording of Intervals
Intervals recorded: PR, QRS, QT, QTcF
Time frame: From screening up to 28 days post-dose
Number and percentage of subjects with abnormal actual QTcF (Fridericia-corrected QT Interval).
Time frame: Part 1 and 2 only: From screening up to 28 days post-dose
Number and percentage of subjects with abnormal change from the baseline of QTcF and HR from 0 to 24 hours
Time frame: Part 1 and 2 only: From screening up to 28 days post-dose
Number of subjects and percentages by treatment with abnormal parameters derived from 24h Holter ECG recording (total pauses >2.5 secs, atrial fibrillation and atrial flutter, ventricular runs, PAC burden, PVC burden and aberrant morphologies)
Time frame: Part 1 and 2 only: From screening up to 28 days post-dose
Number of subjects with abnormal blood laboratory test results
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics.
Time frame: From screening up to 28 days post-dose
Number of subjects with abnormal urine laboratory test results
Time frame: From screening up to 28 days post-dose
Spirometry (FEV1 (Forced exhalation volume in the first second))
Time frame: From screening up to 28 days post-dose
Cough recording: percentage of days with cough episodes during the treatment period
Time frame: Part 2 only: From first dosing up to 28 days post-dose
Cough recording: average VAS (visual analogue scale))
Time frame: Part 2 only: From first dosing up to 28 days post-dose
CHF10073 plasma AUCt (Area Under the Curve from time 0 to time t)
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma Cmax (Maximum Plasma Concentration)
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma AUCinf (Area Under the Curve from time 0 Extrapolated to Infinity)
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma tmax (Time to Maximum Plasma Concentration)
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma elimination half-life
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma apparent clearance (CL/F)
Time frame: From first dosing up to 42 days post-dose
CHF10073 plasma apparent volume of distribution (Vz/F)
Time frame: From first dosing up to 42 days post-dose
CHF10073 urine amount excreted (Ae)
Time frame: Part 1, 2 and 4 : From first dosing up to 28 days post-dose
CHF10073 urine faction excreted (fe)
Time frame: Part 1, 2 and 4: From first dosing up to 28 days post-dose
CHF10073 renal clearance (CLr)
Time frame: Part 1, 2 and 4: From first dosing up to 28 days post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Feb 2026, 12 months.
Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.